ABSTRACT
Background β-haemoglobinopathies are the most common monogenic disorders worldwide. They present with extreme clinical heterogeneity, which makes generalized therapeutic approaches often ineffective. Currently available risk stratification approaches are either too complicated to be deployed at a primary healthcare level or are limited in their applicability across the spectrum of haemoglobinopathies. All current systems also classify patients into the three categories of mild, moderate and severe, where the moderate category is not well-characterized in terms of their expected prognosis.
Methods The current study proposes a severity scoring scheme, utilizing five clinical parameters, viz., steady-state average pre-transfusion haemoglobin, age at presentation, transfusion interval, palpable splenomegaly and growth retardation to classify patients of various β-haemoglobinopathies into severe and non-severe categories. The study then proceeds to validate this scoring scheme on a clinically heterogeneous cohort of 224 Eastern Indian β-thalassaemia and β-haemoglobinopathy patients, and evaluate the predictive performance of the proposed scheme against a clinical standard.
Results All of the chosen parameters except steady-state haemoglobin display strong individual contribution to the final determination of severity, though steady-state haemoglobin conferred increased discriminatory power to the overall scheme. The proposed system achieved an accuracy of 94% against the clinical standard.
Conclusions The proposed risk stratification strategy, being almost entirely empirically-determined, should possess wider applicability across the spectrum of β-haemoglobinopathies than currently existing systems, and should also be more suitable than said systems for studying genotype-phenotype correlations especially within the Eastern Indian β-haemoglobinopathy population.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
Authors are thankful to DST SERB, FIST and PURSE support. The authors are also thankful to the Department of Biotechnology, Govt. of India for supporting this work [Sanc. No-BT/PR26461/MED/12/821/2018].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Burdwan, Clinical Ethics Committee has given approval for the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
If the raw data is needed it will be provdied on request with proper procedure
